The AAPS Journal 2006; 8 (4) Article 78 (http://www.aapsj.org).

Themed Issue: NIDA/AAPS Symposium on Drugs of Abuse: Mechanisms of Toxicity, Toxicokinetics and Medical Consequences, November 4-5, 2005

Guest Editors - Rao S. Rapaka and Jagitsing H. Khalsa

Vesicular Monoamine Transporter 2: Role as a Novel Target for Drug Development

Submitted: June 30, 2006; Accepted: July 18, 2006; *Published: November 10, 2006*

Guangrong Zheng,[1] Linda P. Dwoskin,[1] and Peter A. Crooks[1]

[1]College of Pharmacy, University of Kentucky, Department of Pharmaceutical Sciences, Lexington, KY 40536-0082

ABSTRACT

In the central nervous system, vesicular monoamine transporter 2 (VMAT2) is the only transporter that moves cytoplasmic dopamine (DA) into synaptic vesicles for storage and subsequent exocytotic release. Pharmacologically enhancing DA sequestration by VMAT2, and thus preventing the oxidation of DA in the cytoplasm, may be a strategy for treating diseases such as Parkinson's disease. VMAT2 may also be a novel target for the development of treatments for psychostimulant abuse. This review summarizes the possible role of VMAT2 as a therapeutic target, VMAT2 ligands reported in the literature, and the structure-activity relationship of these ligands, including tetrabenazine analogs, ketanserin analogs, lobeline analogs, and 3-amine-2-phenylpropene analogs. The molecular structure of VMAT2 and its relevance to ligand binding are briefly discussed.

KEYWORDS: vesicular monoamine transporter 2, Parkinson's disease, psychostimulant abuse, tetrabenazine, ketanserin, lobeline

INTRODUCTION

The vesicular monoamine transporter (VMAT), a member of the vesicular neurotransmitter transporter family, is responsible for the translocation of monoamines (serotonin, dopamine, norepinephrine, and histamine) from the cytoplasm into synaptic vesicles via a proton electrochemical gradient generated by the vacuolar type H^+-adenosine triphosphatase.[1] Two pharmacologically distinct VMAT isoforms, VMAT1 and VMAT2, have been cloned and described.[2-4] Adult human and rodent monoaminergic neurons of the central nervous system (CNS) and sympathetic postganglionic neurons express only VMAT2,[5-7] while VMAT1 is predominantly expressed in neuroendocrine cells such as chromaffin cells of the adrenal medulla and enterochromaffin cells of the intestinal tract.[5-7] VMAT2 is also expressed in at least 2 endocrine cell populations and in neurons.[6] Both VMAT1 and VMAT2 are more widely expressed during embryonic development.[8] Substrate recognition and inhibitor sensitivities for differences between VMAT1 and VMAT2 have been studied using membrane vesicles prepared from stable transformed cell lines from Chinese hamster ovaries (CHO) that express the respective proteins.[9] VMAT2 has a consistently higher affinity for all of the monoamine substrates tested, particularly histamine, and has a greater sensitivity than VMAT1 to the inhibitor tetrabenazine (TBZ).

The natural alkaloid reserpine and TBZ are considered 2 classical VMAT inhibitors.[10] Reserpine inhibits the transport of amines into chromaffin granules and synaptic storage vesicles[11,12] by binding with high affinity to VMAT, presumably at the amine recognition site. It has been suggested that TBZ, on the other hand, binds to a site on VMAT that is different from the substrate binding site at which reserpine interacts.[12-14]

VMAT2 AND NEUROPROTECTION

Oxidative deamination of monoamines by monoamine oxidase is accompanied by the reduction of molecular oxygen to a toxic product, hydrogen peroxide.[15] Therefore, maintenance of low cytoplasmic concentrations of neurotransmitters by their reuptake into synaptic vesicles for storage is important to minimize their inherent toxicity.[16] Furthermore, storage of neurotransmitters in synaptic vesicles precludes their metabolism in the cytoplasmic compartment and reduces the synthetic demands on the cell.[16] In the central nervous system, VMAT2 is the only transporter that moves cytoplasmic dopamine (DA) into synaptic vesicles for storage and subsequent exocytotic release.[1]

Parkinson's disease is a degenerative, progressive disorder that dramatically affects neurons of the substantia nigra and the basal ganglia. The etiology of Parkinson's disease has not been elucidated, but exposure to endogenous or environmental toxins may contribute to the development of the disease.[17-21] In this regard, DA may play a role as an endogenous toxin, since the normal metabolism of DA produces hydrogen peroxide as a byproduct, and the formation of DA-associated reactive oxygen species may contribute to

Corresponding Author: Peter A. Crooks, College of Pharmacy, University of Kentucky, 907 Rose Street, Room 501B, Lexington, KY 40503. Tel: (859) 257-1718; Fax: (859) 257-7585; E-mail: pcrooks@email.uky.edu

the loss of nigrostriatal DA neurons.[22] Accordingly, pharmacologically enhancing DA sequestration by VMAT2, and thus preventing the oxidation of DA in the cytoplasm, may be a strategy for treatment of Parkinson's disease.

Exposure to the neurotoxin *N*-methyl-4-phenyltetrahydropyridine (MPTP) results in clinical symptoms closely approximating Parkinson's disease.[17] *N*-Methyl-4-phenylpyridinium (MPP^+), the active toxic metabolite of MPTP, is a substrate for VMAT2.[23-27] VMAT2 sequesters MPP^+ in synaptic vesicles and thereby protects catecholamine-containing neurons from MPP^+-induced toxicity and degeneration.[3,28-32] CHO cells, which are normally sensitive to MPP^+ toxicity, because they lack a plasma membrane amine transporter, can be made relatively insensitive to MPP^+ toxicity by transfection with VMAT complementary DNA.[3] In addition, when the transfected CHO cells are treated with reserpine, which inhibits VMAT2 function, the cells then become sensitive to MPP^+ toxicity.[3] Other studies using heterozygous VMAT2 knockout mice show that the knockouts are more susceptible to the neurotoxic effects of MPTP compared with the wild-type mice.[28,30,33] Furthermore, heterozygous VMAT2 knockout mice are more sensitive to methamphetamine-induced neurotoxicity and are more vulnerable to the toxic effects of L-3,4-dihydroxyphenylalanine (L-DOPA, a DA precursor used to treat Parkinson's disease) compared with wild-type mice.[34,35] The latter results suggest that reduction in VMAT2 activity might attenuate the efficacy of L-DOPA therapy in Parkinson's patients. Finally, increased sequestration of DA in synaptic vesicles by VMAT2 has been suggested to be protective in Parkinson's disease.[36]

Recently, studies have suggested that pharmacological agents that increase VMAT2 activity are neuroprotective. For example, methylphenidate increases vesicular DA uptake in rats and prevents persistent dopaminergic deficits induced by high-dose methamphetamine administration.[37,38] Pramipexole, a DA D2/D3 agonist used as a therapy for Parkinson's disease, increases vesicular DA uptake and protects against the loss of nigrostriatal DA neurons in methamphetamine-, 3-acetylpyridine-, and ischemia-induced neurotoxicity.[39-41] Additionally, apomorphine, a DA D2/D3 agonist used in Europe as a treatment for Parkinson's disease and for impotence, increases vesicular DA uptake, and this mechanism has been suggested to be important for its associated neuroprotection.[42]

Taken together, the results of the above studies indicate that VMAT2 expression and function are important in counteracting the neurotoxicity of MPP^+ and perhaps of other environmental and endogenous neurotoxins that play an etiologic role in neurodegenerative disease.[21]

VMAT2 and Psychostimulant Abuse

Psychostimulant-induced behavioral activation and reinforcement are mediated, at least in part, via interaction with neurotransmitter transporters that regulate synaptic DA concentrations.[43-45] Recent studies have demonstrated that psychostimulants alter VMAT2 function.[46,47] Cocaine inhibits DA transporter function, induces a rapid and reversible increase in vesicular DA uptake and dihydrotetrabenazine (DTBZ) binding, and causes a shift in the ratio of cytoplasmic to vesicular DA, all of which suggests that VMAT2 may be a novel target for the development of treatments for cocaine abuse.[48] Amphetamine and its analogs, such as methamphetamine, decrease vesicular DA sequestration by inhibiting vesicular uptake and promoting release from the vesicles.[49,50] Amphetamine diffuses across the vesicular membrane, decreasing the pH gradient, which results in the loss of free energy needed for monoamine sequestration.[49-52] Also, amphetamine that accumulates in the vesicles competes with monoamines for protons, resulting in an increase in the diffusion of uncharged monoamines out of the vesicle.[52] High-dose methamphetamine treatment decreases vesicular DA uptake and DTBZ binding, suggesting that there is a significant alteration in VMAT2 function and localization at the vesicular membrane.[53] VMAT2 heterologous knockout mice exhibit reduced amphetamine-conditioned place preference (reward) and enhanced sensitivity to the locomotor effects of apomorphine, ethanol, cocaine, and amphetamine.[28,54] VMAT2 knockout studies also indicate that VMAT2 plays an important role in mediating the behavioral effects of psychostimulants. Taken together, these results support the idea that VMAT2 should be considered as a valid target for the development of pharmacotherapies to treat psychostimulant abuse. Other evidence supporting the role of VMAT2 in psychostimulant pharmacology is the finding that benzoquinolizine derivatives, such as TBZ, which have high affinity for VMAT2, decrease locomotor activity and aggressiveness in monkeys[55] and decrease methamphetamine-induced hyperactivity in rodent animal models.[55]

VMAT2 Ligands

TBZ and Its Analogs

TBZ (**1**, Figure 1), a benzoquinolizine compound, has been shown to deplete cerebral monoamines in rat brain by reversibly inhibiting VMAT2.[56] First introduced in 1956 as an antipsychotic drug,[57] TBZ is currently used to treat hyperkinetic movement disorders, such as chorea associated with Huntington's disease, tics in Tourette's syndrome, and movement stereotypes in tardive dyskinesia.[58-60] The side effects associated with TBZ include sedation, depression, akathisia, and parkinsonism.[58] TBZ inhibits catecholamine uptake by VMAT2 with a K_i of 3 nM[14] and acts as an inhibitor of both presynaptic and postsynaptic DA receptors in rat brain.[61] [^{11}C]TBZ (label on the 9-*O*-methyl group) has been synthesized[62] and used as an in vivo radioligand for positron emission tomography (PET) imaging of VMAT2.[63-66]



Figure 1. Structures of tetrabenazine and its analogs (**1-4**).

TBZ analogs have been synthesized with different alkyl groups at the C-3 position in the molecule, such as compound Ro 4-1632 (**2**, Figure 1). These analogs retain good amine-depleting activity.[55]

In vivo, TBZ is rapidly and extensively metabolized to its reduced form, DTBZ (**3**, Figure 1).[67] [^{3}H]DTBZ (label on the C-2 hydrogen) has been used as a selective radioligand in in vitro brain homogenate binding studies and in autoradiographic studies, and is reported to have a K_d value of 3.0 nM.[13,14,68-70] [^{11}C]DTBZ (label on the 9-*O*-methyl group) has also been synthesized[71] and used for in vivo PET imaging of VMAT2.[66,72]

TBZ contains 2 chiral carbon centers at C-3 and C-11b; thus, theoretically, TBZ can exist as 4 possible stereoisomers (3R,11bR; 3S,11bS; 3R,11bS; and 3S,11bR). TBZ usually refers to the racemic compound, that is, a 1:1 mixture of the 3R,11bR and 3S,11bS isomers. Synthetic DTBZ, the product of hydride reduction of the 2-keto group of TBZ, can exist in 2 α-DTBZ forms (2R,3R,11bR, **3a**; and 2S,3S,11bS, **3b**, Figure 2) and 2 β-DTBZ forms (2S,3R,11bR, **3c**; and 2R,3S,11bS, **3d**, Figure 2). α-DTBZ and β-DTBZ can be separated by column chromatography, and the α-DTBZ isomer (K_i = 6 nM) shows slightly higher binding affinity in vitro for rat brain VMAT2 than does β-DTBZ (K_i = 20 nM).[73] The 2 enantiomers of α-DTBZ have been separated using chiral High Performance Liquid Chromatography (HPLC). The (+)-isomer (2R,3R,11bR, **3a**)[74] shows high affinity in vitro (K_i = 0.97 nM) for rat VMAT2, whereas the (–)-isomer shows very low affinity for VMAT2 (K_i = 2.2 μM). Thus the binding of α-DTBZ to VMAT2 is enantioselective, with the (+)-isomer having higher affinity.[75,76]

Another 4 possible DTBZ isomers (2S,3S,11bR, **3e**; 2R,3R,11bS, **3f**; 2R,3S,11bR, **3g**; 2S,3R,11bS, **3h**, Figure 3) have been synthesized and tested for inhibition of VMAT2 binding using rat vesicular membranes. Isomer **3g** showed the highest affinity (K_i = 28 nM) in the [^{3}H]DTBZ binding assay.[77,78]

Methoxytetrabenazine (MTBZ) (**4**, Figure 1) is another TBZ analog with high affinity (K_d = 3.9 nM) for VMAT2.[79] Similar to DTBZ, [^{3}H] and [^{11}C]MTBZ have also been synthesized[73] and used in in vitro and in vivo studies.[79-81]

Nucleophilic addition of organometallic reagents to the C-2 keto group of TBZ generated a series of 2-alkylated DTBZ analogs, such as the 2-Me, 2-Et, 2-Pr, 2-iso-Pr, and 2-iso-Bu derivatives (all racemic mixtures, Figure 4).[82-85] These compounds have been evaluated for inhibition of [^{3}H]MTBZ binding to VMAT2 in rat striatum.[85] The β-methyl compound **5a** showed the highest affinity (K_i = 2.6 nM) in this series, with a nearly 5-fold higher affinity than its diastereomer **5b** (K_i = 12 nM), which is consistent with the finding that α-DTBZ exhibits higher affinity for VMAT2 than does β-DTBZ.[73] Compound **5b** and compounds **6 to 9** all contain a β-hydroxyl group and showed a general decrease in binding affinity upon either lengthening or branching of the alkyl group at C-2.[85] These results indicate that analogs containing considerable steric bulk at position 2 can be tolerated. Thus, compound **10** (Figure 4), in which an ^{125}I atom has been introduced for autoradiographic studies of VMAT2, has been synthesized.[86] (±)-Compound **10** can be separated by chiral HPLC into its optical isomers, and the first eluted enantiomer binds to VMAT2 with a K_d of 0.22 nM.[87]

Structure-activity relationship (SAR) studies involving TBZ analogs have shown that quaternization of the amine nitrogen at position 5, aromatization of ring C, and elimination of the carbonyl group afforded compounds that were devoid



Figure 2. Stereoisomers of dihydrotetrabenazine (**3a-d**).



Figure 3. Stereoisomers of dihydrotetrabenazine (**3e-h**).



Figure 4. Structures of tetrabenazine analogs (**5a-b** and **6-10**).

of monoamine-depleting activity.[55,88] Thus, a basic amine nitrogen at position 5 is a prerequisite for TBZ-like activity.[89] Also, methoxy groups at positions 9 and 10 appear to be essential for TBZ-like activity; the methylenedioxy compound **11** (Figure 5) was 3 orders of magnitude less potent than Ro 4-1284 (**6**).[90]

Replacing the carbonyl oxygen in TBZ with a *bis*-methylthio group (compound **12**, Figure 5) affords a compound with similar activity to TBZ.[91] Olefination of the carbonyl group to afford compound **13** (Figure 5) (EC_{50} = 14 nM) resulted in potent inhibition of [^{3}H]DTBZ binding.[92]

Based upon a limited number of TBZ analogs (**14-17**, Figure 6), a correlation between the lipophilicity of the analogs and their affinity for the DTBZ binding site has been established.[93] Compounds shown to have higher partition coefficients (octanol/buffer) generally exhibited a greater ability to inhibit the specific binding of [^{3}H]DTBZ (IC_{50} = 6 nM for **14**, 47 nM for **17**, 110 nM for **16**, and 2500 nM for **15**) to VMAT2.[93] Accordingly, compound **20** (Figure 6), an iodinated and photosensitive derivative of TBZ, has been synthesized and exhibited an IC_{50} of 428 nM to inhibit [^{3}H]DTBZ binding.[92] However, both its precursor (compound **18**, IC_{50} = 8.1 nM) and the non-iodinated analog (**19**, IC_{50} = 53 nM) of compound **20** showed higher affinity at VMAT2 than did compound **20**.[92]

Several derivatives of compound **16** (ie, compounds **21-24**, Figure 7) have been synthesized; of these, the amino compounds **21** and **22** retained affinity for VMAT2 (K_i = 7.6 nM and 72.2 nM, respectively, in the [^{125}I]iodovinyl-TBZ binding assay), whereas the amido compounds **23** and **24** exhibited diminished affinity for VMAT2 (K_i = 730 nM and >10 000 nM, respectively, in the [^{125}I]iodovinyl-TBZ binding assay).[94]

Ketanserin and Its Analogs

Ketanserin (**25**, Figure 8), a well-known serotonin 5-HT2 receptor antagonist,[95] also binds to VMAT on chromaffin



Figure 5. Structures of tetrabenazine analogs (**11-13**).



Figure 6. Structures of tetrabenazine analogs (**14-20**).

granules and synaptic vesicles.[96-98] In the studies by Darchen et al,[96] Henry et al,[97] and Leysen et al,[98] ketanserin competitively inhibited the binding of [^{3}H]DTBZ to VMAT2, and conversely, TBZ displaced [^{3}H]ketanserin binding. [^{3}H]Ketanserin binds to the TBZ binding site with a K_d of 45 nM at 30ºC and a K_d of 6 nM at 0ºC.[96]

A ketanserin derivative, 7-azidoketanserin (**26**, Figure 8), also binds to the TBZ binding site of bovine chromaffin granule membranes with a K_i of 23 nM (inhibition of [^{3}H]DTBZ binding).[99] An iodinated azido derivative of ketanserin, 7-azido-8-iodoketanserin (**27**, Figure 8), binds to the same specific TBZ binding site as ketanserin with a K_d of 5.5 nM at 0ºC[99]; 7-azido-8-[^{125}I]iodoketanserin has been successfully used for photoaffinity labeling of TBZ binding sites of different tissues, including rat striatum, rabbit platelets, human pheochromocytoma, and human adrenal medulla.[99]

Lengthening the distance between the piperidine and the benzoyleneurea moieties of the ketanserin molecule by addition of 2 methylene groups results in a compound (**28**, Figure 9) that exhibits a 20-fold decrease in affinity (K_i = 950 nM) for the [^{3}H]DTBZ binding site.[96] Reducing the keto group of ketanserin (compound **29**, Figure 9) also decreases affinity (K_i = 350 nM) for this site. Additionally, replacing the benzoyleneurea moiety with other heterocycles (eg, compounds **30-32**, Figure 9) also decreases affinity (K_i = 950, 814, and 3600 nM, respectively) for the [^{3}H]DTBZ binding site. However, minor structural changes to the



Figure 7. Structures of tetrabenazine analogs (**21-24**).



Figure 8. Structures of ketanserin and its analogs (**25-27**).

benzoyleneurea moiety, such as introducing a hydroxyl group into the ring (compound **33**, Figure 9) or replacing 1 of the oxygen atoms with a sulfur atom (compound **34**, Figure 9), retains the affinity (K_i = 14 and 40 nM, respectively).[96]

Lobeline and Its Analogs

A lipophilic alkaloid from *Lobelia inflata*, (–)-lobeline (lobeline, 2R,6S,10S-, **35**, Figure 10), displaces [^{3}H]nicotine binding from native nicotinic receptors in the CNS with high affinity (K_i = 4-30 nM).[100-104] Although lobeline has no structural resemblance to nicotine, and SARs do not suggest a common pharmacophore,[105] it has many nicotinelike effects, such as tachycardia and hypertension,[106] bradycardia and hypotension in anesthetized rats,[107] anxiolytic activity,[108] and improvement of learning and memory.[109] In contrast to nicotine, lobeline only marginally supports self-administration in mice[110] and does not support self-administration in rats.[111] Additionally, chronic lobeline treatment does not increase locomotor activity in rats and does not produce conditioned place preference.[112,113] Thus, lobeline and nicotine have different effects in behavioral and



Figure 9. Structures of ketanserin analogs (**28-34**).



Figure 10. Structure of lobeline (**35**).

neurochemical studies, suggesting that they do not act via a common mechanism. Nevertheless, lobeline has often been considered to be a nicotinic receptor agonist. Conversely, we and others have established that lobeline acts as a potent, but nonselective, nicotinic receptor antagonist.[104,114-117] Lobeline inhibits nicotine-evoked [^{3}H]DA overflow from rat striatal slices with an IC_{50} of 1 μM, suggesting that lobeline acts as an antagonist at nicotinic receptors mediating nicotine-evoked DA release (ie, α6β2β3* subtype).[116] Lobeline also inhibits nicotine-evoked $^{86}Rb^+$ efflux from rat thalamic synaptosomes with an IC_{50} of 0.7 μM, indicating that lobeline is also an antagonist at α4β2* nicotinic receptors.[116] Moreover, lobeline also inhibits [^{3}H]methyllycaconitine binding to rat brain membranes with a K_i of 6.26 μM, indicating that there is an interaction with the α7* nicotinic receptor subtype.[117] Lobeline has also been reported to be an antagonist (IC_{50} of 8.5 μM) at human α7* nicotinic receptors expressed in *Xenopus* oocytes.[118]

In addition to interacting with nicotinic acetylcholine receptors (nAChRs), lobeline inhibits [^{3}H]DTBZ binding to VMAT2 with an IC_{50} of 0.90 μM and inhibits [^{3}H]DA uptake into rat striatal vesicle preparations with an IC_{50} of 0.88 μM.[119,120] Therefore, lobeline is a nonselective nAChR antagonist that also inhibits VMAT2 function. Importantly, lobeline has been shown to inhibit both the neurochemical and the behavioral effects of amphetamine in rodents.[111,121-123] The mechanism underlying the lobeline-induced inhibition of these effects has been suggested to be noncompetitive inhibition of VMAT2 function.[114] The observation that lobeline is not self-administered is consistent with findings that lobeline does not evoke DA release.[111,114,119] Furthermore, the observation that lobeline inhibits methamphetamine-evoked DA release from superfused rat striatal slices[116] is consistent with its ability to decrease methamphetamine self-administration in rats.[123] These studies clearly implicate VMAT2 as a potential target for the development of agents to treat methamphetamine abuse. Regardless, lobeline is a novel prototypical molecule from which subtype-selective nAChR ligands and selective VMAT2 inhibitors may be developed following appropriate structural modification.

Systematic structural modification of the lobeline molecule provided 2 non-oxygen-containing lobeline analogs: *N*-methyl-2,6-di-(*cis*-phenylethenyl)piperidine (*meso*-transdiene [MTD], **36a**, Figure 11) and *N*-methyl-2,6-di-(*cis*-phenylethyl)piperidine (lobelane, **37a**, Figure 11). The latter



Figure 11. Structures of lobeline analogs (**36a-c** and **37a-c**).

2 analogs showed affinity for VMAT2 at the TBZ binding site (K_i of 9.88 μM for **36a**, and 0.97 μM for **37a**), with negligible affinity for the ligand binding sites on α4β2* and α7* nAChRs.[117,124] Compounds **36b** and **36c** (Figure 11) are 2 stereoisomers of **36a**; **36c** was equipotent with its *meso*-isomer, MTD, but **36b** was slightly less potent (2- to 3-fold) than MTD at VMAT2. Within the lobelane series of compounds (ie, compounds **37a**, **37b**, and **37c**, Figure 11), a change in C2, C6 stereochemistry from *cis* to *trans* afforded a modest reduction (5- to 6-fold) in affinity at VMAT2. The *trans* enantiomers **37b** and **37c** exhibited comparable affinities at VMAT2. These data indicate that the VMAT2 binding site is not sensitive to major stereochemical changes to the MTD and lobelane molecules at the C2 and C6 piperidino ring carbons.

Interestingly, 2 conformationally flexible, ring-opened compounds, **38a** and **38b** (Figure 12) (K_i = 5.21 and 3.96 μM, respectively) and 2 acyclic compounds, **39** and **40** (Figure 12) (K_i = 2.37 and 3.07 μM, respectively), exhibited lower, but comparable, affinity for VMAT2 compared with lobelane. Thus, ring opening or complete removal of the piperidine ring results in only a modest reduction in affinity at VMAT2 compared with lobelane (**37a**). The presence of a basic amine functionality is likely a prerequisite for VMAT2 recognition, as is evidenced by the fact that quaternized compounds **41** (K_i > 100 μM) and **42** (K_i = 16.5 μM) (Figure 12) show significant loss in affinity for VMAT2.[124]

The entire lobelane structure appears to be critical for high-affinity binding at VMAT2, since fragments of lobelane or MTD, such as compounds **43** and **44** (Figure 13) (both K_i > 100 μM), exhibited no affinity for VMAT2.[125]



Figure 12. Structures of lobeline analogs (**38a-b** and **39-42**).



Figure 13. Structures of lobeline analogs (**43** and **44**).

Isomerized lobelane analogs, such as compound **45** (Figure 14) (K_i = 1.36 μM), retained affinity for VMAT2, indicating that the position of the piperidine *N* atom relative to the C2 and C6 side chains does not appear to be critical for VMAT2 interaction, and that the VMAT2 binding site can tolerate changes in distance between the piperidine nitrogen and the 2 phenyl rings.[125] In the lobelane structure, changes in the *N*-substituent can also be tolerated. *Nor*-lobelane (**46**, K_i = 2.31 μM), *nor*-*N*-ethyl lobelane (**47**, K_i = 3.41 μM), and *nor*-*N*-n-propyl lobelane (**48**, K_i = 1.87 μM) (Figure 14) exhibit only a slight decrease in affinity for VMAT2 compared with lobelane.[125] Replacing the phenyl rings of lobelane with naphthalene rings (compound **49**, K_i = 0.63 μM) or introducing substituents into the phenyl rings (eg, in compounds **50**, K_i = 0.57 μM; **51**, K_i = 0.43 μM; and **52**, K_i = 0.52 μM) (Figure 14) retains or somewhat improves affinity at VMAT2.

To increase the rigidity of the lobelane molecule, analogs were prepared in which the piperidine ring has been replaced with a tropene ring. The resulting compounds (**53**, K_i = 1.30 μM; **54**, K_i = 1.38 μM; and **55**, K_i = 4.80 μM) (Figure 15) exhibited affinity at VMAT2 comparable with lobelane.[126]

3-Amino-2-Phenylpropene Derivatives

Recently, a series of 3-amino-2-phenylpropene derivatives (Figure 16) have been reported as novel competitive inhibitors of the bovine chromaffin granule membrane monoamine transporter (bVMAT2).[127] With a K_i of 40.3 μM, 3-amino-2-phenylpropene (APP, **56**) inhibits DA uptake into bVMAT2. Introduction of a hydroxyl group into the 3 or 4



Figure 14. Structures of lobeline analogs (**45-52**).



Figure 15. Structures of lobeline analogs (**53-55**).

position of APP affords compounds **57** (K_i = 16.7 μM) and **58** (K_i = 15.5 μM), respectively, equally improved potency for bVMAT2. However, compound **59** (K_i = 103 μM), which has a methoxyl group at the 4 position of the phenyl ring of APP, led to a decrease in potency. However, compound **60**, in which a methoxyl group is at the 3 position of the phenyl ring, led to a slight improvement in inhibitory potency with respect to APP. Methyl (**61**, K_i = 55.9 μM) or fluoro (**62**, K_i = 42.3 μM) substitution at the 4 position of the phenyl ring had no effect on the inhibitory potency, while chloro (**63**), bromo (**64**), and iodo (**65**) substitution led to a modest increase in inhibitory potency (K_i = 18.0, 17.7, and 12.9 μM, respectively).

VMAT2 Structure and Molecular Basis for Binding

Predictions regarding the molecular structure of VMAT2 from its protein sequence are that it comprises 12 putative transmembrane domains (TMDs) with both N- and C- termini in the cytoplasm and a large, hydrophobic, *N*-glycosylated loop between TMDs 1 and 2 facing the vesicle lumen.[1] Structural biology studies have identified important residues that may contribute to ligand binding and monoamine transport. Mutagenesis studies indicate that aspartate 33, which contains a negative charge, in TMD1 and serines 180 to 182 in TMD3 of VMAT2 play a critical role in substrate recognition, presumably by interacting with the protonated amino group of the ligand and hydroxyl groups on the catechol or indole ring, respectively.[128] In addition, lysine 139 in TMD2 and aspartate 427 in TMD11 of VMAT2 interact



56 $R_1 = R_2 = H$
57 $R_1 = OH, R_2 = H$
58 $R_1 = H, R_2 = OH$
59 $R_1 = H, R_2 = OCH_3$
60 $R_1 = OCH_3, R_2 = H$
61 $R_1 = H, R_2 = CH_3$
62 $R_1 = H, R_2 = F$
63 $R_1 = H, R_2 = Cl$
64 $R_1 = H, R_2 = Br$
65 $R_1 = H, R_2 = I$

Figure 16. Structures of 3-amino-2-phenylpropene and its analogs (**56-65**).

to form an ion pair and appear to provide a structural framework for substrate recognition.[129] Experiments employing a chimera of VMAT1 and VMAT2 indicate that 2 domains, TMD5 through TMD8 and TMD9 through TMD12, cooperate to confer the high-affinity interaction of VMAT2 with TBZ and histamine.[130] In addition, the domain encompassing TMD3 and TMD4 influences serotonin affinity but not histamine affinity or TBZ sensitivity.[130] The domain encompassing TMD5 through TMD7 of VMAT2 in the context of N-terminal VMAT2 sequences reduces the apparent affinity for serotonin but not histamine or the sensitivity to TBZ.[130] Tyrosine 434 and aspartate 461 in TMD9 through TMD12 are identified as being responsible for the high-affinity interaction of TBZ, histamine, and serotonin, but not for DA.[131] Photoaffinity labeling of purified rat VMAT2 indicates that TMD1 and TMD10/11 are possibly juxtaposed and may interact in a functionally significant manner.[132] Cysteine mutagenesis and derivatization of human VMAT2 revealed that cysteines 439, 476, and/or 497, and possibly cysteines 126 and/or 333, are important for [^{3}H]TBZOH binding, and cysteines 176, 207, and 439 together are important for [^{3}H]serotonin transport.[133] Furthermore, a disulfide bond between lumenal cysteine 126 in loop 1/2 and cysteine 333 in loop 7/8 has been identified.[134]

Conclusion

Significant progress has been made over the last 20 years in elucidating the role of VMAT2 in monoamine transport and its potential as a therapeutic target. VMAT2 sequesters cytoplasmic DA and thus prevents the oxidation of DA in the cytoplasm; VMAT2 also sequesters neurotoxins within vesicles. These data indicate that VMAT2 may play a role in neuroprotection and that molecules that interact with VMAT2 may have value as treatments for diseases such as Parkinson's disease. VMAT2 may also be a novel target for the development of treatments for psychostimulant abuse, and the discovery of molecules that modulate VMAT2 function may afford useful tools for examining the pivotal role of this transporter in the neurochemical and behavioral effects of psychostimulant drugs, thus providing potential pharmacotherapies.

Acknowledgments

This study was supported by National Institutes of Health grant DA 13519.

References

1. Yelin R, Schuldiner S. Vesicular neurotransmitter transporters: pharmacology, biochemistry, and molecular analysis. In: Reith MEA, ed. *Neurotransmitter Transporters; Structure, Function, and Regulation.* 2nd.Totowa, NJ: Humana Press; 2002:313-354.

2. Erickson JD, Eiden LE, Hoffman BJ. Expression cloning of a reserpine-sensitive vesicular monoamine transporter. *Proc Natl Acad Sci USA*. 1992;89:10993-10997.

3. Liu Y, Peter D, Roghani A, et al. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter. *Cell*. 1992;70:539-551.

4. Erickson J, Eiden L. Functional identification and molecular cloning of a human brain vesicle monoamine transporter. *J Neurochem*. 1993;61:2314-2317.

5. Erickson JD, Schaefer MKH, Bonner TI, Eiden LE, Weihe E. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. *Proc Natl Acad Sci USA*. 1996;93:5166-5171.

6. Peter D, Liu Y, Sternini C, de Giorgio R, Brecha N, Edwards RH. Differential expression of two vesicular monoamine transporters. *J Neurosci*. 1995;15:6179-6188.

7. Weihe E, Schafer MK, Erickson JD, Eiden LE. Localization of vesicular monoamine transporter isoforms (VMAT1 and VMAT2) to endocrine cells and neurons in rat. *J Mol Neurosci*. 1994;5:149-164.

8. Hansson SR, Mezey E, Hoffman BJ. Ontogeny of vesicular monoamine transporter mRNAs VMAT1 and VMAT2, II: expression in neural crest derivatives and their target sites in the rat. *Brain Res Dev Brain Res*. 1998;110:159-174.

9. Peter D, Jimenez J, Liu Y, Kim J, Edwards RH. The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. *J Biol Chem*. 1994;269:7231-7237.

10. Pletscher A. Effect of neuroleptics and other drugs on monoamine uptake by membranes of adrenal chromaffin granules. *Br J Pharmacol*. 1977;59:419-424.

11. Scherman D, Henry JP. Reserpine binding to bovine chromaffin granule membranes. *Mol Pharmacol*. 1984;25:113-122.

12. Darchen F, Scherman D, Henry JP. Reserpine binding to chromaffin granules suggests the existence of two conformations of the monoamine transporter. *Biochemistry*. 1989;28:1692-1697.

13. Henry JP, Scherman D. Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. *Biochem Pharmacol*. 1989;38:2395-2404.

14. Scherman D, Jaudon P, Henry JP. Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine. *Proc Natl Acad Sci USA*. 1983;80:584-588.

15. Cohen G, Kesler N. Monoamine oxidase and mitochondrial respiration. *J Neurochem*. 1999;73:2310-2315.

16. Liu Y, Edwards RH. The role of vesicular transport proteins in synaptic transmission and neural degeneration. *Annu Rev Neurosci*. 1997;20:125-156.

17. Langston JW. The etiology of Parkinson's disease with emphasis on the MPTP story. *Neurology*. 1996;47:S153-S160.

18. Snyder SH, D'Amato RJ. MPTP: a neurotoxin relevant to the pathophysiology of Parkinson's disease. *Neurology*. 1986;36:250-258.

19. Jenner P, Schapira AHV, Marsden CD. New insights into the cause of Parkinson's disease. *Neurology*. 1992;42:2241-2250.

20. Jenner P, Dexter DT, Sian J, Schapira AHV, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. *Ann Neurol*. 1992;32:S82-S87.

21. German DC, Sonsalla PK. A role for the vesicular monoamine transporter (VMAT2) in Parkinson's disease. *Adv Behav Biol*. 2003;54:131-137.

22. Adams JD, Jr, Chang ML, Klaidman L. Parkinson's disease—redox mechanisms. *Curr Med Chem*. 2001;8:809-814.

23. Scherman D, Darchen F, Desnos C, Henry JP. 1-Methyl-4-phenylpyridinium is a substrate of the vesicular monoamine uptake system of chromaffin granules. *Eur J Pharmacol*. 1988;146:359-360.

24. Daniels AJ, Jr, Reinhard JF, Jr. Energy-driven uptake of the neurotoxin 1-methyl-4-phenylpyridine into chromaffin granules via the catecholamine transporter. *J Biol Chem*. 1988;263:5034-5036.

25. Darchen F, Scherman D, Henry JP. Characteristics of the transport of quaternary ammonium 1-methyl-4-phenylpyridine by chromaffin granules. *Biochem Pharmacol*. 1988;37:4381-4387.

26. Del Zompo M, Piccardi MP, Ruiu S, Quartu M, Gessa GL, Vaccari A. Selective MMP+ uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity. *Br J Pharmacol*. 1993;109:411-414.

27. Moriyama Y, Amakatsu K, Futai M. Uptake of the neurotoxin, 4-methylphenylpyridinium, into chromaffin granules and synaptic vesicles: a proton gradient drives its uptake through monoamine transporter. *Arch Biochem Biophys*. 1993;305:271-277.

28. Takahashi N, Miner LL, Sora I, et al. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. *Proc Natl Acad Sci USA*. 1997;94:9938-9943.

29. Speciale SG, Liang CL, Sonsalla PK, Edwards RH, German DC. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter. *Neuroscience*. 1998;84:1177-1185.

30. Gainetdinov RR, Fumagalli F, Wang YM, et al. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. *J Neurochem*. 1998;70:1973-1978.

31. German DC, Liang CL, Manaye KF, Lane K, Sonsalla PK. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. *Neuroscience*. 2000;101:1063-1069.

32. Staal RGW, Sonsalla PK. Inhibition of brain vesicular monoamine transporter (VMAT2) enhances 1-methyl-4-phenylpyridinium neurotoxicity in vivo in rat striata. *J Pharmacol Exp Ther*. 2000;293:336-342.

33. Mooslehner KA, Chan PM, Xu W, et al. Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. *Mol Cell Biol*. 2001;21:5321-5331.

34. Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, Caron MG. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. *J Neurosci*. 1999;19:2424-2431.

35. Kariya S, Takahashi N, Hirano M, Ueno S. Increased vulnerability to L-DOPA toxicity in dopaminergic neurons from VMAT2 heterozygote knockout mice. *J Mol Neurosci*. 2005;27:277-280.

36. Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. *Hum Mol Genet*. 2005;15:299-305.

37. Sandoval V, Riddle EL, Hanson GR, Fleckenstein AE. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. *J Pharmacol Exp Ther*. 2002;304:1181-1187.

38. Hanson GR, Sandoval V, Riddle E, Fleckenstein AE. Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implications. *Ann N Y Acad Sci*. 2004;1025:146-150.

39. Hall ED, Andrus PK, Oostveen JA, Althaus JS, VonVoigtlander PF. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. *Brain Res*. 1996;742:80-88.

40. Sethy VH, Wu H, Oostveen JA, Hall ED. Neuroprotective effects of the dopamine agonist pramipexole and bromocriptine in 3-acetylpyridine-treated rats. *Brain Res*. 1997;754:181-186.

41. Truong JG, Rau KS, Hanson GR, Fleckenstein AE. Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegeneration. *Eur J Pharmacol*. 2003;474:223-226.

42. Truong JG, Hanson GR, Fleckenstein AE. Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegeneration. *Eur J Pharmacol*. 2004;492:143-147.

43. Amara SG, Sonders MS. Neurotransmitter transporters as molecular targets for addictive drugs. *Drug Alcohol Depend*. 1998;51:87-96.

44. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. *Psychol Rev*. 1987;94:469-492.

45. Koob GF. Neural mechanisms of drug reinforcement. *Ann N Y Acad Sci*. 1992;654:171-191.

46. Fleckenstein AE, Hanson GR. Impact of psychostimulants on vesicular monoamine transporter function. *Eur J Pharmacol*. 2003;479:283-289.

47. Riddle EL, Fleckenstein AE, Hanson GR. Role of monoamine transporters in mediating psychostimulant effects. *AAPS J*. 2005;7:E847-E851.serial online.

48. Brown JM, Hanson GR, Fleckenstein AE. Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. *J Pharmacol Exp Ther*. 2001;296:762-767.

49. Sulzer D, Maidment NT, Rayport S. Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. *J Neurochem*. 1993;60:527-535.

50. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. *J Neurosci*. 1995;15:4102-4108.

51. Johnson RG. Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport. *Physiol Rev*. 1988;68:232-307.

52. Sulzer D, Rayport S. Amphetamine and other psychostimulants reduce pH gradients in midbrain dopaminergic neurons and chromaffin granules: a mechanism of action. *Neuron*. 1990;5:797-808.

53. Brown JM, Hanson GR, Fleckenstein AE. Methamphetamine rapidly decreases vesicular dopamine uptake. *J Neurochem*. 2000;74:2221-2223.

54. Wang Y, Gainetdinov RR, Fumagalli F, et al. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. *Neuron*. 1997;19:1285-1296.

55. Pletscher A, Brossi A, Gey KF. Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action. *Int Rev Neurobiol*. 1962;4:275-306.

56. Pettibone DJ, Pflueger AB, Totaro JA. Tetrabenazine-induced depletion of brain monoamines: mechanism by which desmethylimipramine protects cortical norepinephrine. *Eur J Pharmacol*. 1984;102:431-436.

57. Brossi A, Lindlar H, Walter M, Schnider O. Synthesis in the emetine series, I: 2-oxohydrobenzo[a]quinolizines. *Helv Chim Acta*. 1958;41:1793-1806.

58. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. *Expert Rev Neurother*. 2006;6:7-17.

59. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease. *Neurology*. 2006;66:366-372.

60. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. *Neurology*. 1997;48:358-362.

61. Reches A, Burke RE, Kuhn CM, Hassan MN, Jackson VR, Fahn S. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. *J Pharmacol Exp Ther*. 1983;225:515-521.

62. DaSilva JN, Kilbourn MR, Mangner TJ. Synthesis of [11C]tetrabenazine, a vesicular monoamine uptake inhibitor, for PET imaging studies. *Appl Radiat Isot*. 1993;44:673-676.

63. Kilbourn MR, DaSilva JN, Frey KA, Koeppe RA, Kuhl DE. In vivo imaging of vesicular monoamine transporters in human brain using [11C]tetrabenazine and positron emission tomography. *J Neurochem*. 1993;60:2315-2318.

64. DaSilva JN, Kilbourn MR, Domino EF. In vivo imaging of monoaminergic nerve terminals in normal and MPTP-lesioned primate brain using positron emission tomography (PET) and [11C]tetrabenazine. *Synapse*. 1993;14:128-131.

65. DaSilva JN, Carey JE, Sherman PS, Pisani TJ, Kilbourn MR. Characterization of [11C]tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter. *Nucl Med Biol*. 1994;21:151-156.

66. Kilbourn MR. PET radioligands for vesicular neurotransmitter transporters. *Med Chem Res*. 1994;5:113-126.

67. Schwartz DE, Bruderer H, Rieder J, Brossi A. Metabolic studies of tetrabenazine, a psychotropic drug in animals and man. *Biochem Pharmacol*. 1966;15:645-655.

68. Scherman D, Raisman R, Ploska A, Agid Y. [3H]Dihydrotetrabenazine, a new in vitro monoaminergic probe for human brain. *J Neurochem*. 1988;50:1131-1136.

69. Masuo Y, Pelaprat D, Scherman D, Rostene W. [3H]Dihydrotetrabenazine, a new marker for the visualization of dopaminergic denervation in the rat striatum. *Neurosci Lett*. 1990;114:45-50.

70. Zucker M, Weizman A, Rehavi M. Characterization of high-affinity [3H]TBZOH binding to the human platelet vesicular monoamine transporter. *Life Sci*. 2001;69:2311-2317.

71. Jewett DM, Kilbourn MR, Lee LC. A simple synthesis of [11C]dihydrotetrabenazine (DTBZ). *Nucl Med Biol*. 1997;24:197-199.

72. Koeppe RA, Frey KA, Kume A, Albin R, Kilbourn MR, Kuhl DE. Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography. *J Cereb Blood Flow Metab*. 1997;17:919-931.

73. DaSilva JN, Kilbourn MR, Mangner TJ. Synthesis of a [11C]methoxy derivative of alpha-dihydrotetrabenazine: a radioligand for studying the vesicular monoamine transporter. *Appl Radiat Isot*. 1993;44:1487-1489.

74. Kilbourn MR, Lee LC, Heeg MJ, Jewett DM. Absolute configuration of (+)-dihydrotetrabenazine, an active metabolite of tetrabenazine. *Chirality*. 1997;9:59-62.

75. Kilbourn MR, Lee L, Vander Borght T, Jewett D, Frey K. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. *Eur J Pharmacol*. 1995;278:249-252.

76. Kilbourn MR, Lee LC, Jewett DM, Vander Borght TM, Koeppe RA, Frey KA. In vitro and in vivo binding of α-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. *J Cereb Blood Flow Metab*. 1995;15:S650.

77. Clarke I,Turtle R, Johnston G, inventors. Cambridge Laboratories Limited, UK, assignee. Preparation of dihydrotetrabenazines with affinity for monoamine transporters for use in pharmaceutical compositions for the treatment of hyperkinetic disorders.WO 2 005 077 946. February11, 2005.

78. Tridgett R, Clarke I, Turtle R, Johnston G, inventors. Cambridge Laboratories Limited, UK, assignee. Preparation of dihydrotetrabenazine isomers for the treatment of hyperkinetic movement disorders.GB 2 410 947. February11, 2004.

79. Vander Borght TM, Sima AAF, Kilbourn MR, Desmond TJ, Kuhl DE, Frey KA. [3H]Methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity. *Neuroscience*. 1995;68:955-962.

80. Vander Borght TM, Kilbourn MR, Koeppe RA, et al. In vivo imaging of the brain vesicular monoamine transporter. *J Nucl Med*. 1995;36:2252-2260.

81. Kilbourn MR, Sherman PS, Abbott LC. Mutant mouse strains as models for in vivo radiotracer evaluations: [11C]methoxytetrabenazine ([11C]MTBZ) in tottering mice. *Nucl Med Biol*. 1995;22:565-567.

82. F. Hoffmann-La Roche & Co inventor. F. Hoffmann-La Roche & Co, assignee. Substituted 2-hydroxy-1,2,3,4,6,7-hexahydrobenzo[a]quinolizines and their salts.GB 839 105. June 29, 1960.

83. F. Hoffmann-La Roche & Co. inventor. F. Hoffmann-La Roche & Co, assignee. Benzo[a]quinolizine derivatives. BE 633 559. December 13, 1963.

84. F. Hoffmann-La Roche & Co. inventor. F. Hoffmann-La Roche & Co, assignee. Substituted tetrahydrobenzo[a]quinolizines. BE 636 798. March 2, 1964.

85. Lee LC, Vander Borght T, Sherman PS, Frey KA, Kilbourn MR. In vitro and in vivo studies of benzoisoquinoline ligands for the brain synaptic vesicle monoamine transporter. *J Med Chem*. 1996;39:191-196.

86. Canney DJ, Guo YZ, Kung MP, Kung HF. Synthesis and preliminary evaluation of an iodovinyl-tetrabenazine analog as a marker for the vesicular monoamine transporter. *J Labelled Compd Radiopharm*. 1993;33:355-368.

87. Kung MP, Canney DJ, Frederick D, Zhuang Z, Billings JJ, Kung HF. Binding of 125I-iodovinyltetrabenazine to CNS vesicular monoamine transport sites. *Synapse*. 1994;18:225-232.

88. Clarke FH, Hill RT, Koo J, et al. A series of hexahydro[1,4]oxazino[3,4-a]isoquinolines as potential neuroleptics. *J Med Chem*. 1978;21:785-791.

89. Fahrenholtz KE, Capomaggi A, Lurie M, Goldberg MW, Kierstead RW. Octahydrophenanthrene analogs of tetrabenazine. *J Med Chem*. 1966;9:304-310.

90. Saner A, Pletscher A. A benzo[a]quinolizine derivative with a neuroleptic-like action on cerebral monoamine turnover. *J Pharmacol Exp Ther*. 1977;203:556-563.

91. Harnden MR, Short JH. 2-Thio-1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-2H-benzo[a]quinolizines. *J Med Chem*. 1967;10:1183-1184.

92. Aranda G, Beaucourt JP, Ponchant M, Isambert MF, Henry JP. Synthesis and biological activity of iodinated and photosensitive derivatives of tetrabenazine. *Eur J Med Chem*. 1990;25:369-374.

93. Scherman D, Gasnier B, Jaudon P, Henry JP. Hydrophobicity of the tetrabenazine-binding site of the chromaffin granule monoamine transporter. *Mol Pharmacol*. 1988;33:72-77.

94. Canney DJ, Kung MP, Kung HF. Amino- and amido-tetrabenazine derivatives: synthesis and evaluation as potential ligands for the vesicular monoamine transporter. *Nucl Med Biol*. 1995;22:527-535.

95. Leysen JE, Niemegeers CJE, Van Nueten JM, Laduron PM. [3H]Ketanserin (R-4-1468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. *Mol Pharmacol*. 1982;21:301-314.

96. Darchen F, Scherman D, Laduron PM, Henry JP. Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. *Mol Pharmacol*. 1988;33:672-677.

97. Henry JP, Gasnier B, Isambert MF, Darchen F, Scherman D. Ketanserin as a ligand of the vesicular monoamine transporter. *Adv Biosci*. 1991;82:147-150.

98. Leysen JE, Eens A, Gommeren W, Van Gompel P, Wynants J, Janssen PAJ. Identification of nonserotonergic [3H]ketanserin binding sites associated with nerve terminals in rat brain and with platelets; relation with release of biogenic amine metabolites induced by ketanserin- and tetrabenazine-like drugs. *J Pharmacol Exp Ther*. 1988;244:310-321.

99. Isambert MF, Gasnier B, Laduron PM, Henry JP. Photoaffinity labeling of the monoamine transporter of bovine chromaffin granules and other monoamine storage vesicles using 7-azido-8-[125I]iodoketanserin. *Biochemistry*. 1989;28:2265-2270.

100. Yamada S, Isogai M, Kagawa Y, et al. Brain nicotinic acetylcholine receptors: biochemical characterization by neosurugatoxin. *Mol Pharmacol*. 1985;28:120-127.

101. Lippiello PM, Fernandes KG. The binding of L-[3H]nicotine to a single class of high affinity sites in rat brain membranes. *Mol Pharmacol*. 1986;29:448-454.

102. Banerjee S, Abood LG. Nicotine antagonists: phosphoinositide turnover and receptor binding to determine muscarinic properties. *Biochem Pharmacol*. 1989;38:2933-2935.

103. Broussolle EP, Wong DF, Fanelli RJ, London ED. In vivo specific binding of [3H]L-nicotine in the mouse brain. *Life Sci*. 1989;44:1123-1132.

104. Damaj MI, Patrick GS, Creasy KR, Martin BR. Pharmacology of lobeline, a nicotinic receptor ligand. *J Pharmacol Exp Ther*. 1997;282:410-419.

105. Barlow RB, Johnson O. Relations between structure and nicotine-like activity: X-ray crystal structure analysis of (-)-cytisine and (-)-lobeline hydrochloride and a comparison with (-)-nicotine and other nicotine-like compounds. *Br J Pharmacol*. 1989;98:799-808.

106. Olin BR, Hebel SK, Gremp JL, Hulbertt MK. Smoking deterrents. In: Olin BR, Hebel SK, Gremp JL, Hulbertt MK, eds. *Drug Facts and Comparisons.* St. Louis, MO: JB Lippincott; 1995:3087-3095.

107. Sloan JW, Martin WR, Bostwick M, Hook R, Wala E. The competitive binding characteristics of nicotine ligands and their pharmacology. *Pharmacol Biochem Behav*. 1988;30:255-267.

108. Brioni JD, O'Neill AB, Kim DJB, Decker MW. Nicotine receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. *Eur J Pharmacol*. 1993;238:1-8.

109. Decker MW, Majchzark MJ, Arneric SP. Effects of lobeline, a nicotine receptor agonist, on learning and memory. *Pharmacol Biochem Behav*. 1993;45:571-576.

110. Rasmussen T, Swedberg MDB. Reinforcing effects of nicotinic compounds: intravenous self-administration in drug-naive mice. *Pharmacol Biochem Behav*. 1998;60:567-573.

111. Harrod SB, Dwoskin LP, Green TA, Gehrke BJ, Bardo MT. Lobeline does not serve as a reinforcer in rats. *Psychopharmacology (Berl)*. 2003;165:397-404.

112. Fudala PJ, Iwamoto ET. Further studies on nicotine-induced conditioned place preference in the rat. *Pharmacol Biochem Behav*. 1986;25:1041-1049.

113. Stolerman IP, Garcha HS, Mirza NR. Dissociation between the locomotor stimulant and depressant effects of nicotinic agonists in rats. *Psychopharmacology (Berl)*. 1995;117:430-437.

114. Dwoskin LP, Crooks PA. A novel mechanism of action and potential use for lobeline as a treatment for psychostimulant abuse. *Biochem Pharmacol*. 2002;63:89-98.

115. Gallardo KA, Leslie FM. Nicotine-stimulated release of [3H]norepinephrine from fetal rat locus coeruleus cells in culture. *J Neurochem*. 1998;70:663-670.

116. Miller DK, Crooks PA, Dwoskin LP. Lobeline inhibits nicotine-evoked [3H]dopamine overflow from rat striatal slices and nicotine-evoked 86Rb+ efflux from thalamic synaptosomes. *Neuropharmacology*. 2000;39:2654-2662.

117. Miller DK, Crooks PA, Zheng G, Grinevich VP, Norrholm S, Dwoskin LP. Lobeline analogues with enhanced affinity and selectivity for plasmalemma and vesicular monoamine transporters. *J Pharmacol Exp Ther*. 2004;310:1035-1045.

118. Briggs CA, McKenna DG. Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonist binding affinity. *Mol Pharmacol*. 1998;37:1095-1102.

119. Teng L, Crooks PA, Sonsalla PK, Dwoskin LP. Lobeline and nicotine evoke [3H]overflow from rat striatal slices preloaded with [3H]dopamine: differential inhibition of synaptosomal and vesicular [3H]dopamine uptake. *J Pharmacol Exp Ther*. 1997;280:1432-1444.

120. Teng L, Crooks PA, Dwoskin LP. Lobeline displaces [3H]dihydrotetrabenazine binding and releases [3H]dopamine from rat striatal synaptic vesicles: comparison with d-amphetamine. *J Neurochem*. 1998;71:258-265.

121. Miller DK, Crooks PA, Teng L, et al. Lobeline inhibits the neurochemical and behavioral effects of amphetamine. *J Pharmacol Exp Ther*. 2001;296:1023-1034.

122. Miller DK, Harrod SB, Green TA, Wong MY, Bardo MT, Dwoskin LP. Lobeline attenuates the locomotor stimulation induced by repeated nicotine administration in rats. *Pharmacol Biochem Behav*. 2003;74:279-286.

123. Harrod SB, Dwoskin LP, Crooks PA, Klebaur JE, Bardo MT. Lobeline attenuates d-methamphetamine self-administration in rats. *J Pharmacol Exp Ther*. 2001;298:172-179.

124. Zheng G, Dwoskin LP, Deaciuc AG, Norrholm SD, Crooks PA. Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter. *J Med Chem*. 2005;48:5551-5560.

125. Zheng G, Dwoskin LP, Deaciuc AG, Zhu J, Jones MD, Crooks PA. Lobelane analogues as novel ligands for the vesicular monoamine transporter-2. *Bioorg Med Chem*. 2005;13:3899-3909.

126. Zheng G, Dwoskin LP, Deaciuc AG, Crooks PA. Synthesis and evaluation of a series of tropane analogues as novel vesicular monoamine transporter-2 ligands. *Bioorg Med Chem Lett*. 2005;15:4463-4466.

127. Perera RP, Wimalasena DS, Wimalasena K. Characterization of a series of 3-amino-2-phenyl-propene derivatives as novel bovine chromaffin vesicular monoamine transporter inhibitors. *J Med Chem*. 2003;46:2599-2605.

128. Merickel A, Rosandich P, Peter D, Edwards RH. Identification of residues involved in substrate recognition by a vesicular monoamine transporter. *J Biol Chem*. 1995;270:25798-25804.

129. Merickel A, Kaback HR, Edwards RH. Charged residues in transmembrane domains II and XI of a vesicular monoamine transporter form a charge pair that promotes high affinity substrate recognition. *J Biol Chem*. 1997;272:5403-5408.

130. Peter D, Vu T, Edwards RH. Chimeric vesicular monoamine transporters identify structural domains that influence substrate affinity and sensitivity to tetrabenazine. *J Biol Chem*. 1996;271:2979-2986.

131. Finn JP, III, Edwards RH. Individual residues contribute to multiple differences in ligand recognition between vesicular monoamine transporters 1 and 2. *J Biol Chem*. 1997;272:16301-16307.

132. Sievert MK, Ruoho AE. Peptide mapping of the [125I]iodoazidok etanserin and [125I]2-N-[(3′-iodo-4′-azidophenyl)propionyl]tetrabenazine binding sites for the synaptic vesicle monoamine transporter. *J Biol Chem*. 1997;272:26049-26055.

133. Thiriot DS, Ruoho AE. Mutagenesis and derivatization of human vesicle monoamine transporter 2 (VMAT2) cysteines identifies transporter domains involved in tetrabenazine binding and substrate transport. *J Biol Chem*. 2001;276:27304-27315.

134. Thiriot DS, Sievert MK, Ruoho AE. Identification of human vesicle monoamine transporter (VMAT2) lumenal cysteines that form an intramolecular disulfide bond. *Biochemistry*. 2002;41: 6346-6353.